Genetic Analysis AS and Thalys Medical Technology Group Launch Microbiome Test in China
Genetic Analysis AS (“GA”) and Thalys Medical Technology Group Corporation (“Thalys”) have announced the launch of a microbiome test for the Consumer Health (D2C) market in China. The test is based on GA’s clinically validated microbiome test, the GA-map® Dysbiosis Test, adapted for the Chinese market.
This strategic partnership marks GA’s entry into the rapidly growing Chinese market through Thalys and their new Independent Clinical Lab (ICL) in Shanghai. The Chinese D2C microbiome testing market, estimated to be worth $50-80 million in 2023, is projected to grow at a CAGR of 20-30%, reaching $200-300 million by 2030. Growth drivers include increased consumer interest in gut health, probiotics, and personalized nutrition, as well as advancements in e-commerce and digital health platforms.
The Thalys microbiome testing service, powered by the GA-map® Dysbiosis Test, will offer consumers a fast and affordable test. Thalys has developed a D2C mobile software allowing customers to subscribe, pay, and view results on their mobile phones. Test results will provide insights into beneficial and potentially harmful gut microbes, along with health and wellness implications, including personalized probiotics recommendations and weight management insights.
Key Partnership Details
- GA will supply reagent kits to Thalys
- Thalys has invested in clinical study activities and developed front-end consumer software
- GA contributed proprietary software and algorithm development
- The partnership is structured as an ongoing collaboration without predefined order volumes
“We are incredibly proud to launch the GA-map® Dysbiosis Test in China’s dynamic Consumer Health market,” said Zheng Wang (James), President of Thalys Group. “This achievement underscores the power of strategic collaboration, combining GA’s globally recognized microbiome technology with Thalys’ expertise in China’s healthcare ecosystem.”
Ronny Hermansen, CEO of GA, added, “We are thrilled to have enabled Thalys to launch the GA-map® Dysbiosis Test in China. This market is characterized by high growth and significant interest in microbiome-related health issues.”
The launch marks the first stage of the Thalys and GA collaboration, with plans to develop and distribute additional tests based on GA’s GA-map® Technology in China.
For more information on Genetic Analysis, please contact: Ronny Hermansen, CEO E-mail: rh@genetic-analysis.com
For more information on Thalys, please contact: Zheng Wang (James), President E-mail: wangzheng@thalys.net.cn
